Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.65 |
| ▸ | FADS1 | O60427 | 3/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339241 | 1.00 | NPC1 (0.70) | NPC1RAB9APTGS1FADS1P2RX1 | |
| SCHEMBL17744848 | 0.91 | PTGS1 (0.75) | NPC1RAB9APTGS1FADS1P2RX1 | |
| SCHEMBL27826357 | 0.87 | NPC1 (0.61) | NPC1RAB9APTGS1FADS1MAOB | |
| SCHEMBL30830441 | 0.86 | PTGS1 (0.69) | NPC1RAB9APTGS1FADS1P2RX1 | |
| SCHEMBL2127535 | 0.86 | PTGS1 (0.69) | NPC1RAB9APTGS1FADS1P2RX1 | |
| SCHEMBL1140055 | 0.85 | PTGS1 (0.68) | NPC1RAB9APTGS1FADS1P2RX1 | |
| SCHEMBL4954215 | 0.84 | PTGS1 (0.67) | NPC1RAB9APTGS1FADS1P2RX1 | |
| SCHEMBL4957349 | 0.84 | LMNA (0.69) | NPC1RAB9APTGS1FADS1P2RX1 | |
| SCHEMBL1961988 | 0.83 | FADS1 (0.73) | NPC1RAB9APTGS1FADS1P2RX1 | |
| SCHEMBL5925259 | 0.83 | MAPT (0.59) | NPC1RAB9APTGS1FADS1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| CN-117510415-A | Synthesis method of quinazolinone compound | 中国人民解放军军事科学院防化研究院 | 2024-02-06 | — | — | CN | disclosed |
| CN-116472292-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| WO-2021239117-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2021-12-02 | — | — | WO | disclosed |
| EP-2660238-B1 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP (CA) | 2015-05-06 | — | — | EP | disclosed |
| EP-2660238-B1 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP (CA) | 2015-05-06 | — | — | EP | disclosed |
| US-8952021-B2 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP. (CA) | 2015-02-10 | — | — | US | disclosed |
| US-8952021-B2 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP. (CA) | 2015-02-10 | — | — | US | disclosed |
| EP-2382194-B1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP (CA) | 2014-03-12 | — | — | EP | disclosed |
| WO-2010079431-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079431-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2010-07-15 | — | — | WO | disclosed |
| EP-1014962-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2007-06-27 | — | — | EP | disclosed |
| US-7067543-B2 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-1014962-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | AFF1, FFAR1, FFAR2 | NPC1 1201/4885RAB9A 1291/4885PTGS1 1909/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | NPC1 3949/4885RAB9A 3280/4885PTGS1 3614/4885 |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | NPC1 1618/4885RAB9A 2658/4885PTGS1 1623/4885 |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | NPC1 3949/4885RAB9A 3280/4885PTGS1 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.